

CRYO CELL INTERNATIONAL INC  
Form 8-K  
October 17, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(D)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported): July 7, 2017**

**CRYO CELL International, Inc.**  
**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**700 Brooker Creek Boulevard, Oldsmar, Florida**

**000-23386**  
**(Commission**

**File No.)**

**22-3023093**  
**(I.R.S. Employer**

**Identification No.)**

**34677**

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (813) 749-2100

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On July 7, 2017, Cryo-Cell International, Inc. (the Registrant ) issued the attached Press Release reporting on financial results for the three months ended May 31, 2017. The press release giving details associated with the Registrant's earnings is attached as Exhibit 99.1 to this report. The information included in Exhibit 99.1 is considered to be furnished under the Securities Exchange Act of 1934.

**Item 9.01. Financial Statements and Exhibits.**

|  |                 |
|--|-----------------|
| Financial Statements of Businesses Acquired. | Not Applicable. |
| Pro Forma Financial Information              | Not Applicable. |
| Shell Company Transactions                   | Not Applicable. |

Exhibits.

Exhibit

| No.  | Description                              |
|------|--|
| 99.1 | <u>Press Release, dated July 7, 2017</u> |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CRYO CELL International, Inc.

DATE: October 17, 2017

By: /s/ David Portnoy  
David Portnoy  
Chairman, Co-CEO